Avapritinib for Systemic Mastocytosis.
Avapritinib
advanced sm
aggressive sm (asm)
c-findings
indolent sm
kit d816v
mast cell leukemia (mcl)
midostaurin
sm with an associated hematologic neoplasm (sm-ahn)
systemic mastocytosis (sm)
Journal
Expert review of hematology
ISSN: 1747-4094
Titre abrégé: Expert Rev Hematol
Pays: England
ID NLM: 101485942
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
23
7
2021
medline:
3
3
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating We provide an overview of SM, including the current therapeutic landscape, and discuss avapritinib in detail: its chemistry and discovery, pharmacodynamic and pharmacokinetic data, current approval status and safety and efficacy profiles in both advanced and non-advanced SM. With a response rate of 75% amongst evaluable patients with AdvSM and marked reductions observed in measures of mast cell and disease burden, avapritinib stands out as a highly effective targeted therapy for this mutant
Identifiants
pubmed: 34289787
doi: 10.1080/17474086.2021.1959315
doi:
Substances chimiques
Pyrazoles
0
Pyrroles
0
Triazines
0
avapritinib
513P80B4YJ
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-696Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States